Mobile

ODM-201 in addition to standard hormone therapy and docetaxel in metastatic hormone-sensitive prostate cancer

Update Il y a 4 ans
Reference: EUCTR2015-002590-38

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

• To demonstrate the superiority in overall survival of ODM-201 in addition to standard androgen deprivation therapy (ADT) and docetaxel over placebo in addition to standard ADT and docetaxel

Inclusion criteria

  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Links